MitoRx Therapeutics
PrivateLast Round
Early Funding
Nov 17, 2025
Total Funding Raised
$12.24M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
MitoRx Therapeutics operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was an Early Funding round in November 2025.
MitoRx Therapeutics is a biotechnology company developing innovative small molecule mitochondrial metabolic modulators for weight loss and metabolic disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MitoRx Therapeutics Comparables
Compare MitoRx Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NRG Therapeutics | 87% | |
| Mitondra Therapeutics | 83% | |
| Pretzel Therapeutics | 83% |
For institutional investors. Book with your work email.
MitoRx Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Nov 17, 2025 | ||||
| Seed | Dec 13, 2023 | ||||
| Seed | Apr 25, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MitoRx Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oshen Holdings SA | Early Funding |
| Longevitytech.fund | Early Funding, Seed |
| UK Innovation & Science Seed Fund | Early Funding, Seed |
| Empirical Ventures | Early Funding |
| Wren Capital | Early Funding, Seed |
| Oxford Technology | Early Funding, Seed |
| Science Angels Syndicate | Early Funding, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 52% MoM.
- Jul 28, 2026
Monthly visitors increased 31% MoM, reaching 2.1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 3, 2026
MitoRx Therapeutics Limited appoints Neil Anderson as Chief Business Officer, effective immediately, to strengthen its business development capabilities as it advances MTRX31 toward the clinic for metabolically unhealthy obesity in the United Kingdom on Nov 3rd '26.
- attends_eventSep 17, 2026
MitoRx Therapeutics Limited is to present new data on MTRX31, its novel mitochondrial-targeted small molecule, at the 62nd EASD Annual Meeting 2026 in Italy on Sep 30th '26.
- hiresSep 15, 2026
MitoRx Therapeutics Limited appoints Mads to its Clinical & Scientific Advisory Board on Sep 15th '26 in United Kingdom to guide development of its lead asset, MTRX31.
- hiresSep 15, 2026
MitoRx Therapeutics Limited appoints Rury to its Clinical & Scientific Advisory Board to help guide the clinical development strategy for MTRX31 in United Kingdom on Sep 15th '26.
- hiresSep 15, 2026
MitoRx Therapeutics Limited appoints Sven to its Clinical & Scientific Advisory Board to guide the clinical development strategy for MTRX31 in the United Kingdom on Sep 15th '26.
For institutional investors. Book with your work email.
MitoRx Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MitoRx Therapeutics's valuation, stock price, and market status.
Is MitoRx Therapeutics a public or private company?
MitoRx Therapeutics is a private company.
What is the current stock price of MitoRx Therapeutics?
MitoRx Therapeutics is a private company, so its shares have no public market price. Caplight tracks MitoRx Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MitoRx Therapeutics worth (valuation)?
Valuation information for MitoRx Therapeutics is not publicly available.
Can I buy MitoRx Therapeutics stock?
MitoRx Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MitoRx Therapeutics's last funding round?
MitoRx Therapeutics's most recent funding round was Early Funding on November 17, 2025.
Who are the main investors in MitoRx Therapeutics?
Key investors in MitoRx Therapeutics include Oshen Holdings SA.
Will MitoRx Therapeutics IPO soon?
No public IPO plans have been announced for MitoRx Therapeutics.
How can I track MitoRx Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in MitoRx Therapeutics's shares on secondary markets.